Mohali NIPER Develops Neuro-E for Stroke Treatment..

Chandigarh : The National Institute of Pharmaceutical Education and Research (NIPER), Mohali, has made a groundbreaking development in stroke treatment with the creation of Neuro-E, a biologic drug designed to help patients suffering from ischemic stroke. This new innovation aims to improve recovery rates and provide a more effective treatment solution compared to existing therapies.

Ischemic strokes, caused by blockages in blood vessels supplying the brain, are among the leading causes of disability and death worldwide. Current treatment options are limited, with most therapies focusing on dissolving clots or managing symptoms post-stroke. Neuro-E is expected to enhance brain recovery, reduce damage, and improve patient outcomes significantly.

According to experts at NIPER Mohali, extensive research and clinical testing have gone into the development of Neuro-E. The biologic works by targeting neural pathways, promoting cell regeneration, and reducing inflammation in the affected brain areas. Researchers believe this could revolutionize stroke management, offering better survival rates and faster recovery times.

The drug has already shown promising results in pre-clinical trials, with significant improvements in neuroprotection and functional recovery. Researchers are now preparing for clinical trials to evaluate the drug’s effectiveness on a larger scale. The ultimate goal is to bring Neuro-E to the market, making it accessible to hospitals and stroke centers across India and beyond.

Health experts emphasize the importance of rapid treatment in stroke cases. With Neuro-E’s potential to aid early intervention, it could significantly reduce the risk of long-term disability. The development aligns with India’s push towards advancing medical research and self-reliance in pharmaceutical innovation.

Apart from stroke treatment, NIPER researchers are exploring additional applications of Neuro-E in treating other neurodegenerative conditions, such as Alzheimer’s and Parkinson’s disease. This breakthrough further solidifies India’s role in cutting-edge medical research and highlights the country’s growing pharmaceutical expertise.

As the final stages of testing and regulatory approvals are underway, NIPER aims to collaborate with pharmaceutical companies and healthcare institutions to ensure a smooth market entry. If successful, Neuro-E could become a game-changer in stroke treatment, improving millions of lives affected by ischemic stroke